Replies to post #139801 on OWC Pharmaceutical Research Corp (OWCP)

[Monksdream]

Get on the wifi and read the complaint against Jeffrey Friedland. This portion is simply egregious.

1. Jeffrey O. Friedland (“Friedland”) engaged in a nearly $7 million securities fraud
scheme to conceal the nature of his interest in an Israeli medical marijuana company, OWC
Pharmaceutical Research Corp. (“OWC”), to allow him to unload his considerable holdings in
OWC stock into a market that he helped artificially inflate. As part of his scheme, Friedland
Case 1:18-cv-00529-MSK Document 1 Filed 03/05/18 USDC Colorado Page 1 of 36
2
touted OWC to investors while misrepresenting both the nature of his investments in OWC and
his professional relationship with the company.
2. In August 2014, Friedland acquired more than 1.3 million shares of restricted
OWC stock when he made an early investment in OWC through one of his companies, Intiva
Pharma LLC (“Intiva”).
3. In February 2016, Friedland acquired another 5.1 million shares of restricted
OWC stock through one of his other companies, Global Corporate Strategies LLC (“Global”), as
compensation for a January 2016 agreement to handle OWC’s media and investor relations in the
United States for a period of two years.
4. Between February 2016 and September 2017, Friedland participated in
interviews, made presentations, and sent out emails discussing his early investment in OWC and
touting OWC to media, industry, and investors. Through these efforts, Friedland created the
false impression that he was merely an early investor in OWC and, as a result of that investment
and his experience and expertise in the nascent medical marijuana industry, he was asked by
OWC to become a member of its advisory board. In fact, Friedland had been paid millions of
shares of stock by OWC to promote the company to the press and investing public, and that stock
constituted more than 75% of his holdings, dwarfing his direct investment interest in OWC.
5. Friedland also made material false statements to potential and actual OWC
investors to induce them either to purchase OWC stock or refrain from selling shares they
already held. Indeed, as OWC’s closing stock price increased from the fall of 2016 to its peak in
early March 2017, Friedland made numerous public appearances on behalf of OWC using his
perceived stature and expertise as an advisor to the company to support its increasing share price,
making false statements to investors that he was a buy-and-hold long-term investor in OWC
when he was in fact making preparations to sell—and at later points actually selling—his OWC